Isalathiso se-adrenaline nasal spray Neffy iye yandiswa (yi-US FDA) ukuze iquke abantwana abaneminyaka emine ubudala nangaphezulu abanobunzima obuphakathi kwe-15 ukuya ngaphantsi kwe-30 kg.
Ngaphambili nge-9 ka-Agasti 2025, Neffy yavunywa kunyango olungxamisekileyo lohlobo loku-1 lokuchasana nokuchasana nomzimba, kubandakanywa nezo zisongela ubomi be-anaphylaxis, kubantu abadala kunye nabantwana abanobunzima ubuncinane be-30 kg (iikhilogram ezingama-66). Yeyokuqala i-FDA evunyiweyo yokutshiza ngeempumlo ukunyanga i-anaphylaxis kunye nemveliso yokuqala ye-epinephrine yonyango lwe-anaphylaxis engalawulwa ngenaliti.
Ngomhla we-28 kuJuni 2024, Eurneffy, isitshizi sokuqala seempumlo se-adrenaline kunyango olungxamisekileyo ngokuchasene nokungaguquki komzimba (anaphylaxis) sanikwa isigunyaziso sentengiso kwi-European Union (EU) yi-European Medicine Agency (EMA).
Isitshizi seempumlo se-adrenaline sonyango olungxamisekileyo ngokuchasene nokungalungelani nokungalungelani komzimba nezinto (anaphylaxis) silindele ukwamkelwa e-United Kingdon naseKhanada.
Ukuvunywa kwe-adrenaline nasal spray kunyango olungxamisekileyo ngokuchasene nokuchaphazeleka komzimba kubonelela ngenye indlela yolawulo lwe-adrenaline kwabo (ingakumbi abantwana) abachasayo kwiinaliti kwaye bajongene nemeko esongela ubomi ye-anaphylaxis.
Adrenaline (ekwaziwa ngokuba yi-epinephrine) kuphela konyango olusindisa ubomi kwi-anaphylaxis. Ifumaneka ukuza kuthi ga ngoku kuphela njengoko inaliti idla ngokusetyenziswa nge-intramuscular (IM) okanye nge-intravenous (IV) indlela. Neffy/Eurneffy yimveliso yokuqala ye-epinephrine yonyango lwe-anaphylaxis engalawulwa ngenaliti. Lithamo elinye lempumlo yokutshiza efakwe kwimpumlo enye. Idosi yesibini (ukusebenzisa isitshizi seempumlo esitsha kwimpumlo enye) inokunikwa ukuba akukho phuculo kwiimpawu okanye iimpawu eziya ziba mandundu. Izigulane zinokufuna uncedo lwezonyango olungxamisekileyo ukuze zibekwe iliso elisondeleyo.
I-Anaphylaxis ithathwa njengengxakeko yonyango. Sisenzo esiyingozi, esisongela ubomi esibandakanya amalungu amaninzi omzimba. Ukutya okuthile, amayeza kunye nokuluma kwezinambuzane zizinto eziqhelekileyo ezinokuthi zibangele i-anaphylaxis. Iimpawu zidla ngokuvela kwimizuzu nje yokuvezwa kwaye zibandakanya, kodwa azikhawulelwanga, ukudumba, ukurhawuzelelwa, ukugabha, ukuphefumla nzima kunye nokulahlekelwa zingqondo.
***
Iingxelo:
- Ukukhutshwa kweendaba ze-FDA -FDA Roundup: 7 Matshi 2025. Ifumaneka e https://www.fda.gov/news-events/press-announcements/fda-roundup-march-7-2025
- EMA. Iindaba - Isitshizi sokuqala se-adrenaline yeempumlo kunyango olungxamisekileyo ngokuchasene nokungaguquki komzimba. Ithunyelwe nge-28 Juni 2024. Ifumaneka apha https://www.ema.europa.eu/en/news/first-nasal-adrenaline-spray-emergency-treatment-against-allergic-reactions
- Iifayile ze-ARS Pharmaceuticals zokuVunywa kwe-neffy® eKhanada nase-United Kingdom egameni loMlingane weLayisensi i-ALK-Abelló A/S. Ithunyelwe nge-6 kaJanuwari 2025. Ifumaneka e https://ir.ars-pharma.com/news-releases/news-release-details/ars-pharmaceuticals-files-approval-neffyr-canada-and-united
***
Inqaku elinxulumene nalo
- Unyango olutsha oluLula lwePeanut allergy (15 Novemba 2018)
***
